BLUE News and Press, bluebird bio Inc. From 01/06/21

I estimate the fair value for BLUE between $5-7 billion based on similar acquisitions. 2021 could be an inflection point with the anticipated approval of the company's multiple myeloma treatment. BLUE's most recent share issuance caused significant dilution, but the value is below...

A Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, Gracell Biotechnologies (GRCL) to raise $150M by offering 8.825M ADSs at a price range of $16 to $18.Underwriters' over-allotment is an additional 1,323,750 ADSs.Net proceeds together with existing cash and cash equiva...

As the American Society of Hematology conference wrapped up, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discussed the best investments in the hematology space. In this video from Motley Fool Live, recorded on Dec. 14, Brian talks abou...

Gracell Biotechnologies has filed to raise $100 million in a U.S. IPO, although the final figure may vary. The firm is developing treatments for various cancers using a CAR-T approach. GRCL has produced very promising Phase 1 trial results for its lead candidate. For further...

The following slide deck was published by bluebird bio, Inc. in conjunction with this event. For further details see: bluebird bio (BLUE) Presents At 2020 ASH Annual Meeting - Slideshow

For many years bluebird bio (NASDAQ: BLUE) has been in the lead for developing a potential cure for beta thalassemia and sickle cell disease. But CRISPR Therapeutics (NASDAQ: CRSP) and its partner Vertex Pharmaceuticals (NASDAQ: VRTX) are looking to compete with a po...

No CEO should be evaluated on their company's stock performance in a single year . Strategies often take several years to play out. When a company's fortunes depend on drug development, the timeline can be even longer. That's why no investor should take it too hard that Galapagos NV ...

Bluebird bio (BLUE) says new data from group C of its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin gene therapy for adults and adolescents patients with sickle cell disease show a complete elimination of severe vaso-occlusive events and VOEs between six and 24 months of foll...

No severe vaso-occlusive events (VOEs) reported through 24 months of follow-up in Group C patients who had a history of at least four severe VOEs and at least six months of follow-up (n=19) At up to 30 months follow-up and 32 patients treated, Group C patients continue to prod...

At the American Society of Hematology annual meeting over the weekend, Johnson & Johnson (JNJ -0.5%) posted attention-getting data on a pair of approaches to multiple myeloma. One study confirmed the company's cilta-cel as the most efficacious CAR-T therapy, with more than three-quarters ...